Advancement of anti‐LAG‐3 in cancer therapy

Abstract

AbstractImmune checkpoint inhibitors have effectively transformed the treatment of many cancers, particularly those highly devastating malignancies. With their widespread popularity, the drawbacks of immune checkpoint inhibitors are also recognized, such as drug resistance and immune‐related systematic side effects. Thus, it never stops investigating novel immune checkpoint inhibitors. Lymphocyte Activation Gene‐3 (LAG‐3) is a well‐established co‐inhibitory receptor that performs negative regulation on immune responses. Recently, a novel FDA‐approved LAG‐3 blocking agent, together with nivolumab as a new combinational immunotherapy for metastatic melanoma, brought LAG‐3 back into focus. Clinical data suggests that anti‐LAG‐3 agents can amplify the therapeutic response of other immune checkpoint inhibitors with manageable side effects. In this review, we elucidate the intercellular and intracellular mechanisms of LAG‐3, clarify the current understanding of LAG‐3 in the tumor microenvironment, identify present LAG‐3‐associated therapeutic agents, discuss current LAG‐3‐involving clinical trials, and eventually address future prospects for LAG‐3 inhibitors.